Email this article Protective activity of mixtures of pneumococcal antigens in infection caused by Streptococcus pneumoniae serotype 3
- Authors: Vorobyev D.S.1,2, Tokarskaya M.M.1, Baranovskaya S.A.1, Stefutushkina E.A.1,2, Afanasyeva O.M.1, Astashkina E.A.1, Zhigunova O.V.1, Volokh Y.V.1, Leonova A.Y.1, Petukhova E.S.1, Semenova I.B.1, Nechaev D.N.2, Kravtsova E.O.2, Ovechko N.N.1, Yastrebova N.E.1, Gruber I.M.1, Mikhailova N.A.1
-
Affiliations:
- I.I. Mechnikov Research Institute of Vaccines and Sera
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
- Issue: Vol 20, No 4 (2021)
- Pages: 59-65
- Section: ORIGINAL REPORTS
- Published: 03.12.2021
- URL: https://bioterapevt.abvpress.ru/jour/article/view/1279
- DOI: https://doi.org/10.17650/1726-9784-2021-20-4-59-65
- ID: 1279
Cite item
Full Text
Abstract
Introduction. Pneumococcal diseases remain relevant for the whole world. On the one hand, this is due to the high prevalence of pneumococcus and the other hand, the growth of antibiotic-resistant strains and the constant change of clinically significant serotypes of the pathogen.
The aim of the research was to study of the protective activity of a mixture of pneumococcal antigens.
Material and methods. we used preparations of a capsular polysaccharide (CPS) obtained from Streptococcus pneumoniae serotype 3; protein-containing fraction (PCF) obtained from an aqueous extract of cells of S. pneumoniae serotype 6B; recombinant pneumolysin (rPly). Mice were immunized intraperitoneally twice with an interval of 14 days with mixtures of bacterial antigens: CPS + PCF; CPS + rPly; PCF + rPly. To assess the protective activity of the studied drugs after double immunization animals were infected intraperitoneally with S. pneumoniae serotype 3. To study the effect of mixtures of bacterial preparations on the infectious process in the lungs immunized mice were infected with S. pneumoniae serotype 3. The humoral immune response was studied with IgG using the method of ELISA.
Results. The CPS + rPly mixture protected mice from intraperitoneal infection with S. pneumoniae serotype 3 regardless of the infecting dose. Immunization with CPS + PCF or CPS + rPly mixtures influenced a significant decrease the number of seeded bacterial cells from lungs during the entire observation period (72 h) compared to the control. Administration of mixtures of bacterial antigens of CPS + PCF, CPS + rPly or PCF + rPly to animals led to a significant increase of the level of antibodies to all antigens, however, the highest levels of IgG were determined to PCF and rPly.
Conclusion. The results obtained suggest that different antigenic drugs in mixtures affect different mechanisms of immunity activation.
About the authors
D. S. Vorobyev
I.I. Mechnikov Research Institute of Vaccines and Sera; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Author for correspondence.
Email: vorobievdenis@yandex.ru
ORCID iD: 0000-0002-1926-8803
Denis Sergeevich Vorobyev
5a Maly Kazenny per., 105064 Moscow
Bld. 2, 8 Trubetskaya St., 119991 Moscow
M. M. Tokarskaya
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-5175-5433
5a Maly Kazenny per., 105064 Moscow
Russian FederationS. A. Baranovskaya
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0003-1769-3811
5a Maly Kazenny per., 105064 Moscow
Russian FederationE. A. Stefutushkina
I.I. Mechnikov Research Institute of Vaccines and Sera; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
ORCID iD: 0000-0002-3209-617X
5a Maly Kazenny per., 105064 Moscow
Bld. 2, 8 Trubetskaya St., 119991 Moscow
O. M. Afanasyeva
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0003-0875-4141
5a Maly Kazenny per., 105064 Moscow
Russian FederationE. A. Astashkina
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0001-6234-0156
5a Maly Kazenny per., 105064 Moscow
Russian FederationO. V. Zhigunova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-3958-6219
5a Maly Kazenny per., 105064 Moscow
Russian FederationYu. V. Volokh
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-5161-4964
5a Maly Kazenny per., 105064 Moscow
Russian FederationA. Yu. Leonova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-2889-2405
5a Maly Kazenny per., 105064 Moscow
Russian FederationE. S. Petukhova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0003-0796-5764
5a Maly Kazenny per., 105064 Moscow
Russian FederationI. B. Semenova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-6630-4838
5a Maly Kazenny per., 105064 Moscow
Russian FederationD. N. Nechaev
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
ORCID iD: 0000-0002-7592-3809
Bld. 2, 8 Trubetskaya St., 119991 Moscow
Russian FederationE. O. Kravtsova
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
ORCID iD: 0000-0002-9100-0422
Bld. 2, 8 Trubetskaya St., 119991 Moscow
Russian FederationN. N. Ovechko
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0001-8550-1290
5a Maly Kazenny per., 105064 Moscow
Russian FederationN. E. Yastrebova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-6911-1345
5a Maly Kazenny per., 105064 Moscow
Russian FederationI. M. Gruber
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-1922-4640
5a Maly Kazenny per., 105064 Moscow
Russian FederationN. A. Mikhailova
I.I. Mechnikov Research Institute of Vaccines and Sera
ORCID iD: 0000-0002-8532-4690
5a Maly Kazenny per., 105064 Moscow
Russian FederationReferences
- Kim L., McGee L., Tomczyk S., Beall B. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and postconjugate vaccine eras: a United States perspective. Clin Microbiol Rev 2016;29(3):525–52. doi: 10.1128/CMR.00058-15.
- Brooks L.R.K., Mias G.I. Streptococcus pneumoniae’s virulence and host immunity: aging, diagnostics, and prevention. Front Immunol 2018;9:1366. doi: 10.3389/fimmu.2018.01366.
- Nishimoto A.T., Rosch J.W., Tuomanen E.I. Pneumolysin: pathogenesis and therapeutic target. Front Microbiol 2020;11:1543. doi: 10.3389/fmicb.2020.01543.
- Weiser J.N., Ferreira D.M., Paton J.C. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol 2018;16(6):355–67. doi: 10.1038/s41579-018-0001-8.
- Masomian M., Ahmad Z., Gew L.T., Poh C.L. Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines (Basel.) 2020;8(1):132. doi: 10.3390/vaccines8010132.
- Cillóniz C., Amaro R., Torres A. Pneumococcal vaccination. Curr Opin Infect Dis 2016;29(2):187–96. doi: 10.1097/qco.0000000000000246.
- Briles D.E., Paton J.C., Mukerji R. et al. Pneumococcal Vaccines. Microbiol Spectr 2019;7(6). doi: 10.1128/microbiolspec.gpp3-0028-2018.
- Ginsburg A.S., Alderson M.R. New conjugate vaccines for the prevention pneumococcal disease in developing countries. Drugs Today 2011;47(3):207–14. doi: 10.1358/dot.2011.47.3.1556471.
- Vaneeva N.P., Vorobyev D.S., Grischenko N.V. et al. Study of crossactivity Streptococcus pneumoniae antigen preparations. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology 2012;5:36–42. (In Russ.).
- Vorobyev D.S., Semenova I.B., Volokh Yu.V. et al. Study of protective activity of Streptococcus pneumoniae protein-containing antigen complex in homologous system. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology 2013;1:21–6. (In Russ.).
- Vorobyev D.S., Semenova I.B., Volokh Yu.V. et al. Study of protective activity of protein-containing antigens of Streptococcus pneumoniae in a heterologous system. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology 2015;6:51–5 (In Russ.).
- Vorobyev D.S., Semenova I.B., Volokh Yu.V. et al. Properties of native protein-containing antigens of Streptococcus pneumoniae. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology 2019;1:22–8. (In Russ.). doi: 10.36233/0372-9311-2019-1-22-28.
- Kukina O.M., Gruber I.M., Akhmatova N.K. et al. Study of the immunobiological properties of surface protein-containing antigens of Streptococcus pneumoniae serotype 6B. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and Vaccinal Prevention 2020;19(3):21–27. (In Russ.). doi: 10.31631/2073-3046-2020-19-3-21-27.
- Vaneeva N.P., Yastrebova N.E. Specific immune response to certain capsule polysaccharides of Streptococcus pneumoniae in healthy blood donors and individuals immunized with pneumococcal vaccines. Zhurnal mikrobiologii, epidemiologii i immunobiologii = Journal of Microbiology, Epidemiology and Immunobiology 2015;5:20–6. (In Russ.).
- Hoover J.L., Lewandowski T.F., Mininger C.L. et al. A robust pneumonia model in immunocompetent rodents to evaluate antibacterial efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii. J Visualized Experiments 2017;119:e55068. doi: 10.3791/55068.
- Glantz S.A. Biomedical statistics. Moscow: Praktika, 1998. Pp. 386–394. (In Russ.).
- Petukhova E.S., Vorobyev D.S., Sidorov A.V. et al. Immunization with recombinant pneumolysin induces the production of antibodies and protects mice in a model of systemic infection caused by Streptococcus pneumoniae. Bulleten experimentalnoy biologii i meditsiny = Bulletin of Experimental Biology and Medicine 2019;168(10):471–3. (In Russ.).
- Yastrebova N.E., Tokarskaya M.M., Baranovskaya S.A. et al. Immunobiological activity of the drug Pneumovic against experimental pneumococcal infection. Biofarmatsevticheskiy Zhurnal = Russian Journal of Biopharmaceuticals 2020;12(5):45–9. (In Russ.).
Supplementary files
